ProQR Therapeutics NV (PRQR)
1.34
+0.10
(+8.06%)
USD |
NASDAQ |
Oct 27, 16:00
1.32
-0.02
(-1.49%)
After-Hours: 20:00
ProQR Therapeutics Enterprise Value : 70.28M for Oct. 27, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 27, 2026 | 70.28M |
| October 26, 2026 | 56.17M |
| October 23, 2026 | 63.22M |
| October 22, 2026 | 68.87M |
| October 21, 2026 | 74.51M |
| October 20, 2026 | 75.92M |
| October 19, 2026 | 66.04M |
| October 16, 2026 | 66.04M |
| October 15, 2026 | 85.80M |
| October 14, 2026 | 88.62M |
| October 13, 2026 | 90.04M |
| October 12, 2026 | 109.79M |
| October 09, 2026 | 111.20M |
| October 08, 2026 | 102.74M |
| October 07, 2026 | 111.20M |
| October 06, 2026 | 114.03M |
| October 05, 2026 | 116.85M |
| October 02, 2026 | 111.91M |
| October 01, 2026 | 111.20M |
| September 30, 2026 | 115.44M |
| September 29, 2026 | 114.03M |
| September 28, 2026 | 114.03M |
| September 25, 2026 | 114.03M |
| September 24, 2026 | 122.49M |
| September 23, 2026 | 121.08M |
| Date | Value |
|---|---|
| September 22, 2026 | 149.31M |
| September 21, 2026 | 143.66M |
| September 18, 2026 | 139.43M |
| September 17, 2026 | 147.90M |
| September 16, 2026 | 143.66M |
| September 15, 2026 | 140.84M |
| September 14, 2026 | 143.66M |
| September 11, 2026 | 143.66M |
| September 10, 2026 | 154.95M |
| September 09, 2026 | 162.01M |
| September 08, 2026 | 170.47M |
| September 04, 2026 | 173.30M |
| September 03, 2026 | 176.12M |
| September 02, 2026 | 184.59M |
| September 01, 2026 | 180.35M |
| August 31, 2026 | 181.76M |
| August 28, 2026 | 204.34M |
| August 27, 2026 | 208.58M |
| August 26, 2026 | 212.81M |
| August 25, 2026 | 217.04M |
| August 24, 2026 | 224.10M |
| August 21, 2026 | 211.40M |
| August 20, 2026 | 201.52M |
| August 19, 2026 | 194.47M |
| August 18, 2026 | 184.59M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Pharming Group NV | 808.61M |
| NewAmsterdam Pharma Co. NV | 1.777B |
| argenx SE | 54.54B |
| Mirum Pharmaceuticals, Inc. | 5.865B |
| ACADIA Pharmaceuticals, Inc. | 2.589B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -10.15M |
| Revenue (Quarterly) | 10.18M |
| Total Expenses (Quarterly) | 20.33M |
| EPS Diluted (Quarterly) | -0.0923 |
| Gross Profit Margin (Quarterly) | 91.93% |
| Profit Margin (Quarterly) | -99.65% |
| Earnings Yield | -34.61% |
| Normalized Earnings Yield | -34.66 |